DK0921395T3 - Assays til måling af proteinfragmenter i biologiske medier - Google Patents

Assays til måling af proteinfragmenter i biologiske medier

Info

Publication number
DK0921395T3
DK0921395T3 DK98309266T DK98309266T DK0921395T3 DK 0921395 T3 DK0921395 T3 DK 0921395T3 DK 98309266 T DK98309266 T DK 98309266T DK 98309266 T DK98309266 T DK 98309266T DK 0921395 T3 DK0921395 T3 DK 0921395T3
Authority
DK
Denmark
Prior art keywords
protein fragments
assays
biological media
measuring protein
collagen
Prior art date
Application number
DK98309266T
Other languages
Danish (da)
English (en)
Inventor
James Thomas Downs
Kimberly Sue Johnson
Peter Steven Mezes
Ivan George Otterness
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK0921395T3 publication Critical patent/DK0921395T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK98309266T 1997-11-13 1998-11-12 Assays til måling af proteinfragmenter i biologiske medier DK0921395T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6542397P 1997-11-13 1997-11-13

Publications (1)

Publication Number Publication Date
DK0921395T3 true DK0921395T3 (da) 2003-07-07

Family

ID=22062616

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98309266T DK0921395T3 (da) 1997-11-13 1998-11-12 Assays til måling af proteinfragmenter i biologiske medier

Country Status (10)

Country Link
US (1) US6030792A (es)
EP (1) EP0921395B1 (es)
JP (1) JP3258630B2 (es)
AT (1) ATE237133T1 (es)
BR (1) BR9804988A (es)
CA (1) CA2254010A1 (es)
DE (1) DE69813158T2 (es)
DK (1) DK0921395T3 (es)
ES (1) ES2194277T3 (es)
PT (1) PT921395E (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US7640083B2 (en) * 2002-11-22 2009-12-29 Monroe David A Record and playback system for aircraft
US6642007B1 (en) * 1998-11-02 2003-11-04 Pfizer Inc. Assays for measurement of type II collagen fragments in urine
WO2000040597A1 (en) * 1999-01-06 2000-07-13 University Of Southern California Method and composition for angiogenesis inhibition
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
CN1379685A (zh) * 1999-07-13 2002-11-13 南加利福尼亚大学 用基于MMP－9和β1整联蛋白的拮抗剂抑制血管发生的新方法和组合物
JP2004520011A (ja) * 2000-08-21 2004-07-08 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療において有用な抗−ｒａｎｋリガンドモノクローナル抗体
AU2001292312A1 (en) * 2000-09-29 2002-04-08 Chugai Seiyaku Kabushiki Kaisha Method of analyzing antibody molecule structure
EP1409536A2 (en) * 2001-02-12 2004-04-21 Curagen Corporation Human proteins and nucleic acids encoding same
US20030040027A1 (en) * 2001-08-16 2003-02-27 Gerd Ritter Method for determining protein component in a biological sample
EP1497646A4 (en) * 2001-08-31 2006-07-19 Pharmacia Corp PEPTIDE BIOMARKER AND METHOD OF IDENTIFICATION
US20040067882A1 (en) * 2001-10-22 2004-04-08 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US20030219843A1 (en) * 2001-12-20 2003-11-27 Welsch Dean J. Methods of diagnosing and treating abnormal growth
US8367013B2 (en) * 2001-12-24 2013-02-05 Kimberly-Clark Worldwide, Inc. Reading device, method, and system for conducting lateral flow assays
US20030119203A1 (en) * 2001-12-24 2003-06-26 Kimberly-Clark Worldwide, Inc. Lateral flow assay devices and methods for conducting assays
CN1649899A (zh) 2002-05-03 2005-08-03 米列姆·贝尔罗吉克公司 结缔组织刺激肽
WO2003102544A2 (en) * 2002-05-31 2003-12-11 Cognosci, Inc. Assays for measuring matrix metalloproteinase activities
US7285424B2 (en) 2002-08-27 2007-10-23 Kimberly-Clark Worldwide, Inc. Membrane-based assay devices
US7432105B2 (en) * 2002-08-27 2008-10-07 Kimberly-Clark Worldwide, Inc. Self-calibration system for a magnetic binding assay
US7488792B2 (en) * 2002-08-28 2009-02-10 Burnham Institute For Medical Research Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
US20040101920A1 (en) * 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US20040106190A1 (en) * 2002-12-03 2004-06-03 Kimberly-Clark Worldwide, Inc. Flow-through assay devices
US7247500B2 (en) * 2002-12-19 2007-07-24 Kimberly-Clark Worldwide, Inc. Reduction of the hook effect in membrane-based assay devices
US20040197819A1 (en) * 2003-04-03 2004-10-07 Kimberly-Clark Worldwide, Inc. Assay devices that utilize hollow particles
US7851209B2 (en) 2003-04-03 2010-12-14 Kimberly-Clark Worldwide, Inc. Reduction of the hook effect in assay devices
US20050112703A1 (en) 2003-11-21 2005-05-26 Kimberly-Clark Worldwide, Inc. Membrane-based lateral flow assay devices that utilize phosphorescent detection
US7713748B2 (en) * 2003-11-21 2010-05-11 Kimberly-Clark Worldwide, Inc. Method of reducing the sensitivity of assay devices
US7943395B2 (en) * 2003-11-21 2011-05-17 Kimberly-Clark Worldwide, Inc. Extension of the dynamic detection range of assay devices
US7943089B2 (en) * 2003-12-19 2011-05-17 Kimberly-Clark Worldwide, Inc. Laminated assay devices
US20050136550A1 (en) * 2003-12-19 2005-06-23 Kimberly-Clark Worldwide, Inc. Flow control of electrochemical-based assay devices
US7521226B2 (en) 2004-06-30 2009-04-21 Kimberly-Clark Worldwide, Inc. One-step enzymatic and amine detection technique
EP1845376A4 (en) * 2005-01-28 2008-07-09 Shionogi & Co QUANTITATIVE MEASURING PROCEDURE FOR RECOMBINANT PROTEIN
WO2007024921A2 (en) * 2005-08-24 2007-03-01 Cell Matrix Combination therapies for inhibiting integrin-extracellular matrix interactions
US8940871B2 (en) * 2006-03-20 2015-01-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
US7858752B2 (en) 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
JP6126773B2 (ja) * 2007-09-04 2017-05-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原（ｐｓｃａ）抗体
EP2740490A1 (en) * 2007-10-03 2014-06-11 Cornell University Treatment of proliferative disorders using antibodies to PSMA
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
ES2712732T3 (es) * 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
WO2011034128A1 (ja) 2009-09-16 2011-03-24 塩野義製薬株式会社 コラーゲンネオエピトープ抗体
EP2506876B1 (en) 2009-12-02 2016-10-12 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
DE102012107651A1 (de) * 2012-08-21 2014-02-27 Astrium Gmbh Verfahren zur Durchführung einer biochemischen Analyse, insbesondere im Weltraum
EP4137158A1 (en) 2015-08-07 2023-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
CN112218657A (zh) * 2018-04-12 2021-01-12 百时美施贵宝公司 Cd73拮抗剂抗体和pd-1/pd-l1轴拮抗剂抗体的抗癌组合疗法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5320970A (en) * 1987-11-06 1994-06-14 Washington Research Foundation Detection of collagen degradation in vivo
US5300434A (en) * 1987-11-06 1994-04-05 Washington Research Foundation Hybridoma cell line producing an antibody to type-I collagen amino-terminal telopeptide
WO1994014070A1 (en) * 1992-12-04 1994-06-23 Shriners Hospitals For Crippled Children Immunoassay for the measurement of collagen cleavage in cartilage
US5541295A (en) * 1993-02-12 1996-07-30 The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations Detection of type II collagen and its peptides
GB9702252D0 (en) * 1997-02-06 1997-03-26 Univ Sheffield Medical The Sch Collagen assay

Also Published As

Publication number Publication date
JPH11218532A (ja) 1999-08-10
ATE237133T1 (de) 2003-04-15
US6030792A (en) 2000-02-29
EP0921395A3 (en) 1999-09-01
JP3258630B2 (ja) 2002-02-18
DE69813158T2 (de) 2003-11-27
EP0921395A2 (en) 1999-06-09
PT921395E (pt) 2003-06-30
CA2254010A1 (en) 1999-05-13
EP0921395B1 (en) 2003-04-09
DE69813158D1 (de) 2003-05-15
ES2194277T3 (es) 2003-11-16
BR9804988A (pt) 2000-03-28

Similar Documents

Publication Publication Date Title
DK0921395T3 (da) Assays til måling af proteinfragmenter i biologiske medier
ATE529509T1 (de) Selektion von proteinen unter verwendung von rna- protein-fusionen
ATE439592T1 (de) Proteingerüste für antikörper-nachahmer und andere bindende proteine
DK1025227T3 (da) Humane TOLL-homologer
DK0943097T3 (da) Fremgangsmåde til at påvise IgE
HUP0200400A2 (hu) Fehérjék izolálása és elemzése
CY1111097T1 (el) Πρωτεϊνη δεσμευσης του υποδοχεα nogo
ES2090001T3 (es) Un metodo para seleccionar por la presencia de un defecto genetico asociado con trombosis y/o una pobre respuesta anticoagulante a la proteina c activada.
ATE393228T1 (de) Fusionsproteine und deren verwendung zur messung von protease-aktivität
ATE509120T1 (de) Fusionsproteine zur detektion von analyten
DE69938867D1 (de) Verfahren und verwendung von anordungen von proteinfixierungsmitteln
BR9916325A (pt) Método para expressão de alto nìvel de proteìnas quiméricas de imunoglobulina de receptor de linfotoxina-beta ativas e sua purificação
ATE382148T1 (de) Antikörper für apoptosemarker und anwendungsverfahren
DE69839444D1 (de) Smad 6 und dessen anwendungen
DE69806107T2 (de) Methoden und reagenzien zur regulierung von apoptosis
AU3169599A (en) Method for screening substance promoting oligomerization of receptor protein molecules
DK1423708T3 (da) Sammensætninger og fremgangsmåder til bestemmelser af AA4RP